{"id":5755,"date":"2025-11-24T15:24:38","date_gmt":"2025-11-24T14:24:38","guid":{"rendered":"https:\/\/oximio.com\/?post_type=oximio-resources&p=5755"},"modified":"2026-02-23T16:15:43","modified_gmt":"2026-02-23T15:15:43","slug":"clinical-trials-canada-report","status":"publish","type":"oximio-resources","link":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/","title":{"rendered":"Clinical Trials in Canada \u2013 How the Country Stands to Benefit in a Changing World"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The global clinical trial landscape is undergoing rapid transformation, shaped by regulatory\u00a0pressures, rising costs, geopolitical uncertainty, and growing demand for diverse patient\u00a0populations. In this shifting environment, Canada is emerging as a strategically positioned\u00a0hub for clinical research.<\/p>

Already ranked among the top ten countries for clinical trials, Canada has the fifth highest\u00a0number of planned clinical trials globally as of December 2024.<\/p>

Canada has the opportunity to strengthen its global standing, with a Mutual Recognition\u00a0Agreement signed with the European Union in 2021, and proximity to the US, the country\u00a0with the most clinical trials in the world.<\/p>

While US tariffs on drug imports pose risks to life sciences investors and sponsors, they also\u00a0highlight Canada\u2019s appeal as a stable, cost-effective, and reliable destination for sponsors\u00a0and investors.<\/p>

Global shifts in clinical trials<\/strong><\/p>

The global clinical development services market, which encompasses clinical trials, was forecast to be worth $61.7bn in 2024 and is expected to grow to $101.5bn by 2030, according to\u00a0GlobalData, representing an 8.6% compound annual growth rate.<\/p>

This growth comes with mounting complexity. Vast amounts of trial data now require intensive\u00a0analysis, while patient recruitment and retention remain persistent challenges. Trials increasingly target narrower patient populations, raising costs and demanding more sophisticated designs.<\/p>

The adoption of adaptive trials during the COVID-19 pandemic demonstrated flexibility but also\u00a0introduced new complexities that drive up research and development expenses. On top of these scientific hurdles, regulatory and policy changes add uncertainty. For example, the US Inflation Reduction Act, which permits direct government negotiations on drug pricing, has raised concerns about reduced pharmaceutical revenues and diminished research and development (R&D) investment.<\/p>

Geopolitical tensions further complicate trial planning. Supply chain instability has disrupted\u00a0access to investigational medicinal products and comparator drugs, while potential retaliation\u00a0from China against the US BIOSECURE Act could sharply increase the cost of running single country trials. Collectively, these pressures are encouraging sponsors to explore more stable markets, creating opportunities for Canada.<\/p>

Planned clinical trials, country, by phase<\/h2>

\"GlobalData<\/p>

Number of planned trials by country and phase.
<\/em>Source: GlobalData Pharma Intelligence Center, as of December 2024.<\/em><\/span><\/p>

Against this backdrop, Canada offers both stability and predictability. The country\u2019s GDP growth\u00a0is forecast at 1.4% in 2025, and it boasts a higher working-age employment rate of 74.7% than\u00a0the US at 71.9%. Within the Americas, Canada is ranked lowest for legal risk and second lowest\u00a0for political risk. Such a combination of economic resilience, political security, and reliable\u00a0institutions makes Canada an increasingly attractive option for investors seeking long-term\u00a0returns on clinical trial activity.<\/p>

Canada\u2019s Competitive Advantage<\/h2>

Canada\u2019s appeal extends beyond stability. The country\u2019s universal healthcare system provides\u00a0free, high-qualitycare accessible across all 13 provinces and territories. This model not only\u00a0facilitates broader patient participation in trials but also removes financial barriers that often\u00a0skew representation in countries with private healthcare models.<\/p>

Furthermore, by fostering collaboration among physicians and therapy area specialists rather\u00a0than competition for patients, Canada creates an environment of trust that supports both\u00a0patient care and the integrity of research.<\/p>

Diversity is another major advantage. With a population of 36.99 million in 2021, Canada\u00a0recorded over 450 ethnic and cultural origins in its census, with racialised groups, including\u00a0Asian, Chinese, and Black communities, comprising 16.1% of the population. A highly educated\u00a0workforce adds to this strength. Such diversity ensures that clinical trials capture data from a\u00a0wide range of patient backgrounds, improving the ability to generalise trial findings.<\/p>

Another important factor the receptiveness of the population to therapy treatments in general.<\/p>

If vaccine hesitancy were to be used as a proxy for willingness to participate in clinical trials, the\u00a0Canadian population is more receptive than that of the US. Specifically, for COVID-19 vaccine\u00a0acceptance and hesitancy in June 2022, 87% of the Canadian population was receptive and\u00a013% was hesitant. In the US, 80.2% was receptive while 19.8% was hesitant. Research has\u00a0found that an increase in the number of \u2018vaccine deniers\u2019 or \u2018anti-vaxxers\u2019 can restrict the pool\u00a0of trial participants.<\/p>

Canada\u2019s academic and research infrastructure further enhances its appeal. The country is\u00a0home to 17 medical schools, 40 groupings of academic healthcare organisations, and more\u00a0than 15,000 researchers. The Canadian Institutes of Health Research allocates more than $1bn\u00a0annually to health research, while the federal and provincial governments collectively invest\u00a0up to $3.2bn in life sciences R&D. Major pharmaceutical investments from Sanofi ($2bn) and\u00a0AstraZeneca ($570m) further underscore confidence in the Canadian life sciences sector.<\/p>

Top Sponsors<\/strong><\/h2>

\"GlobalData<\/p>

Top ten sponsors of completed and ongoing clinical trials in Canada since October 2020.<\/em><\/span><\/p>

Note: The trials data relates to the company role as a sponsor and trials tagged to the parent company.<\/em><\/span><\/p>

Institutions such as the University of Toronto (ranked 21st globally), the University of British\u00a0Columbia (41st), and McGill University (45th) provide world-class research and talent pipelines. In addition, universities are the top three associated organisations for investigators of clinical trials.<\/p>

Investigators by Top 15 Associated Organizations<\/h2>

\"Clinical<\/p>

Top 15 Associated institutions of clinical trials in Phase I-IV, Canada.<\/em><\/span>
Source: GlobalData Pharma Intelligence Center<\/em><\/span><\/p>

This academic strength, coupled with institutions such as the Canadian Clinical Trials<\/p>

Coordinating Centre, provides robust infrastructure for conducting and coordinating studies.<\/p>

The number of clinical trials in Canada ramped up significantly in 2001 when Health Canada\u00a0became the regulatory authority responsible for clinical trial approvals oversight and inspections, in accordance with Canada Food and Drug Regulations. The new regulatory framework was instigated with two main objectives: to strengthen the protections for patients, and increase research and development investment in clinical trials in Canada.<\/p>

The framework also includes fundamental elements of Good Clinical Practices such as ensuring sound clinical research and maintaining accurate records. A major change that this brought about was the shortening of standard review for Phase I trials in healthy volunteers to 60 days to seven days. This more favourable regulatory environment saw life sciences investors move into the Canadian market.<\/p>

Economically, Canada\u2019s pharmaceutical industry was valued at $25.55bn in 2020 and is projected to grow to $27.08bn by 2026, according to GlobalData. Regulatory changes in 2001 also streamlined processes, reducing Phase I clinical trial review times from 60 days to just seven days, while incorporating fundamental elements of Good Clinical Practice. Combined with R&D tax incentives such as the Scientific Research and Experimental Development program, Canada has built a pro-innovation environment that supports trial sponsors from start to finish.<\/p>

Canada also benefits from its geographic position and advanced logistics infrastructure. With\u00a0major trial hubs centres around Toronto, Montreal and Vancouver, sponsors have access\u00a0to world-class airports, seaports and road networks with further investment for continuous\u00a0improvement. The government has the Transportation 2030 strategic plan in place for a national\u00a0transportation system that supports economic growth.<\/p>

One of the themes of this federal plan is Trade Corridors to Global Markets, to optimise the\u00a0flow of goods. There is also the National Trade Corridors Fund which will be funding projects\u00a0until 2028 to improve the fluidity of Canada\u2019s supply chains. As supply chains face increasing\u00a0strain from geopolitical disruption, Canada\u2019s reputation for regulatory compliance and logistical\u00a0reliability positions the country as a standout choice.<\/p>

Clinical Trials in Canada \u2013 The Numbers<\/h2>

As of late-2024, the majority of clinical trials (1,690) were sponsored by companies, according to GlobalData. This is followed by 1,126 by institutions, 168 by individuals or investigators, and 85 by government bodies.<\/p>

Sponsor Type<\/h2>

\"Clinical<\/p>

Top sponsor types of clinical trials in Canada as of late 2024.
<\/em>Source: GlobalData Pharma Intelligence Center<\/em>\u00a0<\/em><\/span><\/p>

Top Therapy Areas<\/h2>

\"Top<\/p>

Top ten therapy areas of ongoing and completed trials in Canada since October 2020.
<\/em>Source: GlobalData Pharma Intelligence Center<\/em><\/span><\/p>

As of September 2025, GlobalData recorded Canada as having 2,865 active or ongoing trials\u00a0in Phases I-IV. By phase, 296 trials were in Phase I, 1,028 in Phase II, 1,165 in Phase III, and\u00a0376 in Phase IV. These figures underscore both the scale and breadth of Canada\u2019s role in\u00a0global clinical research.<\/p>

Trial Phase<\/h2>

\"Clinical<\/p>

Ongoing clinical trials in Canada by phase.
<\/em>Source: GlobalData Pharma Intelligence Center<\/em><\/span><\/p>

Supply chain challenges in clinical trials<\/h2>

Despite these advantages, logistics remains a critical challenge. Clinical trial materials, including drugs, medical devices, and biological samples, must be transported under strict conditions, on time, and in compliance with regulations. Of the 235 planned clinical trials in Canada as of September 2024, GlobalData recorded 175 single-country studies, while 60 (25.5%) were multicountry, highlighting the increasing complexity of international operations.<\/p>

Location Type<\/h2>

\"Clinical<\/p>

Ongoing clinical trials in Canada by phase.<\/span><\/em>
Source: GlobalData Pharma Intelligence Center<\/span><\/em><\/p>

Multi-country trials pose greater challenges due to varying time zones, customs regulations,\u00a0and storage requirements. Effective logistics demand strict temperature control, sourcing and\u00a0distribution networks, and precise storage capabilities. Delays or disruptions can directly affect\u00a0patient safety and compromise trial outcomes. For this reason, sponsors increasingly depend\u00a0on global logistics providers with experience in over 50 countries and the flexibility to navigate\u00a0diverse infrastructures.<\/p>

How 3PL can enable trial success in Canada<\/h2>

Third-party logistics (3PL) providers are critical enablers of trial success. Companies such as\u00a0Oximio can offer these essential services. With more than 20 years of experience and operations across 50 countries, Oximio provides critical support to both large pharmaceutical firms and smaller biotech players.<\/p>

Located in Hamilton, Ontario, Oximio BARL Canada offers a full suite of capabilities. The depot is located within the Greater Toronto and Hamilton Area, home to 7.2 million people. Capabilities offered include handling antibiotics, cytotoxins, dangerous goods, and ancillary supplies, as well as supporting temperature ranges from ambient (15\u00b0C to 25\u00b0C) to deep frozen (-60\u00b0C to -80\u00b0C).<\/p>

Services include labelling (just-in-time), comparator sourcing, importer-of-record services, and\u00a0both direct-to-patient (DTP) and direct-to-site (DTS) delivery. The depot is also certified with GDP and GMP licences. Such infrastructure ensures Canada can support the operational needs of modern trials while maintaining compliance and efficiency.<\/p>

The global clinical trials industry is facing mounting pressures, from rising costs and regulatory\u00a0uncertainty to supply chain challenges and geopolitical disruptions. Within this landscape,\u00a0Canada is carving out a strong position. Its stable political and economic environment, universal healthcare system, diverse population, world-class academic and research networks, and pro-innovation regulatory framework make it an attractive alternative to less predictable markets.<\/p>

With more than 2,800 active trials, growing pharmaceutical investment, and reliable logistics\u00a0infrastructure, Canada stands to consolidate its role as a leading hub for clinical research. For\u00a0sponsors, investors, and patients alike, the country represents not only a safe haven but also a\u00a0strategic opportunity in a rapidly changing world.<\/p>

Companies such as Oximio BARL Canada stand ready to offer the key logistics services required in clinical research.<\/p>

Oximio BARL Canada – Clinical Trial Services<\/h2>

In October 2025, Oximio welcomed Bay Area Research Logistics (BARL), Canada to the Oximio family. This strategic move combines Oximio\u2019s extensive global supply chain expertise with BARL\u2019s considerable experience in North American and global markets and further strengthens, Oximio\u2019s global footprint whilst enhancing its capabilities across the globe.<\/p>

Find out how our tailor-made supply chain services can support your clinical trial in Canada and North America: https:\/\/oximio.com\/network\/canada\/<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":5756,"template":"","meta":{"_acf_changed":false},"resources-categories":[8],"class_list":["post-5755","oximio-resources","type-oximio-resources","status-publish","has-post-thumbnail","hentry","resources-categories-white-paper"],"acf":[],"yoast_head":"\nClinical Trials in Canada | Global Data Report | Services<\/title>\n<meta name=\"description\" content=\"Clinical Trials in Canada | In this 2025 report by Oximio and Global Data, we Explore How the Country Stands to Benefit in a Changing World.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oximio.com\/tr\/resources\/clinical-trials-canada-report\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Trials in Canada | Global Data Report | Services\" \/>\n<meta property=\"og:description\" content=\"Clinical Trials in Canada | In this 2025 report by Oximio and Global Data, we Explore How the Country Stands to Benefit in a Changing World.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Oximio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Oximio\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T15:15:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"1385\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/\",\"url\":\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/\",\"name\":\"Clinical Trials in Canada | Global Data Report | Services\",\"isPartOf\":{\"@id\":\"https:\/\/oximio.com\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg\",\"datePublished\":\"2025-11-24T14:24:38+00:00\",\"dateModified\":\"2026-02-23T15:15:43+00:00\",\"description\":\"Clinical Trials in Canada | In this 2025 report by Oximio and Global Data, we Explore How the Country Stands to Benefit in a Changing World.\",\"breadcrumb\":{\"@id\":\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#primaryimage\",\"url\":\"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg\",\"contentUrl\":\"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg\",\"width\":1280,\"height\":1385,\"caption\":\"Map representing clinical trials in Canada.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/oximio.com\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Trials in Canada \u2013 How the Country Stands to Benefit in a Changing World\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/oximio.com\/tr\/#website\",\"url\":\"https:\/\/oximio.com\/tr\/\",\"name\":\"Oximio\",\"description\":\"We deliver care\",\"publisher\":{\"@id\":\"https:\/\/oximio.com\/tr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/oximio.com\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/oximio.com\/tr\/#organization\",\"name\":\"Oximio\",\"url\":\"https:\/\/oximio.com\/tr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/oximio.com\/tr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/oximio.com\/wp-content\/uploads\/2024\/09\/Oximio_logo-01.jpg\",\"contentUrl\":\"https:\/\/oximio.com\/wp-content\/uploads\/2024\/09\/Oximio_logo-01.jpg\",\"width\":2501,\"height\":1363,\"caption\":\"Oximio\"},\"image\":{\"@id\":\"https:\/\/oximio.com\/tr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Oximio\/\",\"https:\/\/www.linkedin.com\/company\/smo-group\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Trials in Canada | Global Data Report | Services","description":"Clinical Trials in Canada | In this 2025 report by Oximio and Global Data, we Explore How the Country Stands to Benefit in a Changing World.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oximio.com\/tr\/resources\/clinical-trials-canada-report\/","og_locale":"tr_TR","og_type":"article","og_title":"Clinical Trials in Canada | Global Data Report | Services","og_description":"Clinical Trials in Canada | In this 2025 report by Oximio and Global Data, we Explore How the Country Stands to Benefit in a Changing World.","og_url":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/","og_site_name":"Oximio","article_publisher":"https:\/\/www.facebook.com\/Oximio\/","article_modified_time":"2026-02-23T15:15:43+00:00","og_image":[{"width":1280,"height":1385,"url":"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/","url":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/","name":"Clinical Trials in Canada | Global Data Report | Services","isPartOf":{"@id":"https:\/\/oximio.com\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#primaryimage"},"image":{"@id":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#primaryimage"},"thumbnailUrl":"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg","datePublished":"2025-11-24T14:24:38+00:00","dateModified":"2026-02-23T15:15:43+00:00","description":"Clinical Trials in Canada | In this 2025 report by Oximio and Global Data, we Explore How the Country Stands to Benefit in a Changing World.","breadcrumb":{"@id":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#primaryimage","url":"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg","contentUrl":"https:\/\/oximio.com\/wp-content\/uploads\/2025\/11\/clinical-trials-canada-map.jpg","width":1280,"height":1385,"caption":"Map representing clinical trials in Canada."},{"@type":"BreadcrumbList","@id":"https:\/\/oximio.com\/resources\/clinical-trials-canada-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oximio.com\/tr\/"},{"@type":"ListItem","position":2,"name":"Clinical Trials in Canada \u2013 How the Country Stands to Benefit in a Changing World"}]},{"@type":"WebSite","@id":"https:\/\/oximio.com\/tr\/#website","url":"https:\/\/oximio.com\/tr\/","name":"Oximio","description":"We deliver care","publisher":{"@id":"https:\/\/oximio.com\/tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oximio.com\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Organization","@id":"https:\/\/oximio.com\/tr\/#organization","name":"Oximio","url":"https:\/\/oximio.com\/tr\/","logo":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/oximio.com\/tr\/#\/schema\/logo\/image\/","url":"https:\/\/oximio.com\/wp-content\/uploads\/2024\/09\/Oximio_logo-01.jpg","contentUrl":"https:\/\/oximio.com\/wp-content\/uploads\/2024\/09\/Oximio_logo-01.jpg","width":2501,"height":1363,"caption":"Oximio"},"image":{"@id":"https:\/\/oximio.com\/tr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Oximio\/","https:\/\/www.linkedin.com\/company\/smo-group"]}]}},"_links":{"self":[{"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/oximio-resources\/5755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/oximio-resources"}],"about":[{"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/types\/oximio-resources"}],"version-history":[{"count":14,"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/oximio-resources\/5755\/revisions"}],"predecessor-version":[{"id":7163,"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/oximio-resources\/5755\/revisions\/7163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/media\/5756"}],"wp:attachment":[{"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/media?parent=5755"}],"wp:term":[{"taxonomy":"resources-categories","embeddable":true,"href":"https:\/\/oximio.com\/tr\/wp-json\/wp\/v2\/resources-categories?post=5755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}